Investigational drug · Phase 2
Umbilical Cord Mesenchymal Stem Cells
Also called: Mesenchymal stromal cells, Allogeneic Mesenchymal Stem Cells
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Nephropathy Type 2, Ischemic Stroke, Cerebral Palsy.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
477
Any phase or sponsor naming "Umbilical Cord Mesenchymal Stem Cells"
First trial start
2021
Oct 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Umbilical Cord Mesenchymal Stem Cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Nephropathy Type 2
- Ischemic Stroke
- Cerebral Palsy
- Pathologic Processes
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Umbilical Cord Mesenchymal Stem Cells" as an intervention, largest first.
Thomas Advanced Medical LLCIndustry
NCT04684602 · 5,000 participants (planned) · Start Jul 9, 2020 · Primary completion Jul 9, 2030
Drug: PrimePro™/ PrimeMSK™ · For: Autoimmune Diseases; Cardiovascular Disorders; Diabetes Complications and 8 more
Sites: Culver City, California
- Njinsky Ambispective Cellular Product Safety and Outcomes RegistryNot yet recruiting
Njinsky Medical CentreAcademic, hospital or other
NCT07941544 · 1,200 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 30, 2030
Drug: Umbilical Cord Mesenchymal Stem Cells; Stromal Vascular fraction · For: Retinitis Pigmentosa (RP); Autism Disorder; Diminished Ovarian Reserve and 3 more
Sites: Lahore, Pakistan
- Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)Pivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT03818737 · 475 participants · Start Mar 28, 2019 · Primary completion May 31, 2022
Drug: Bone Marrow Derived MSCs; Adipose-derived MSCs and 2 more · For: Osteoarthritis
Sites: Gulf Breeze, Florida; Atlanta, Georgia; Durham, North Carolina · 5 sites in all
- MSCs for Prevention of MI-induced HFPivotal-lookingCompleted
Shiraz University of Medical SciencesAcademic, hospital or other
NCT05043610 · 420 participants · Start Sep 15, 2021 · Primary completion Nov 1, 2024
Drug: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) · For: Myocardial Infarction, Acute; Myocardial Infarction First; Myocardial Infarction, Anterior Wall and 4 more
Sites: Shiraz, Iran · 3 sites in all
- Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee OsteoarthritisPivotal-lookingRecruiting
Shanghai IxCell Biotechnology Co., LTDAcademic, hospital or other
NCT06716281 · 398 participants (planned) · Start Jan 5, 2024 · Primary completion Dec 31, 2025
Drug: Human umbilical cord mesenchymal stem cells; Placebo · For: Knee Osteoarthritis
Sites: Shanghai, China
- Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)Pivotal-lookingStatus unknown
Chinese Academy of SciencesGovernment (non-federal)
NCT03033277 · 320 participants (planned) · Start Feb 2016 · Primary completion Apr 2017
Drug: Placebo transplantation; HUC-MSCs transplantation · For: Primary Ovarian Insufficiency
Sites: Beijing, China
- Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in ChinaPivotal-lookingCompleted
General Hospital of Chinese Armed Police ForcesAcademic, hospital or other
NCT01873547 · 300 participants · Start Jun 2012 · Primary completion Oct 2014
Drug: cell therapy · For: Spinal Cord Injury
Sites: Beijing, China
- WJMSCs Anti-inflammatory Therapy in Coronary Artery DiseasePivotal-lookingStatus unknown
Navy General Hospital, BeijingAcademic, hospital or other
NCT04551456 · 300 participants (planned) · Start Nov 30, 2020 · Primary completion Dec 30, 2021
Drug: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS · For: Coronary Artery Disease
- Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral ParalysisPivotal-lookingCompleted
General Hospital of Chinese Armed Police ForcesAcademic, hospital or other
NCT01929434 · 300 participants · Start Oct 2013 · Primary completion Dec 2015
Drug: stem cell injection · For: Cerebral Palsy
Sites: Beijing, China
- Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic ShockPivotal-lookingRecruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT05969275 · 296 participants (planned) · Start Feb 14, 2024 · Primary completion Sep 30, 2026
Drug: Allogeneic umbilical cord-derived human mesenchymal stromal cells · For: Septic Shock; Sepsis; Pathologic Processes and 4 more
Sites: Ottawa, Canada · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- 3D culture-derived MSC EV facilitate repair by activating microglial autophagy in spinal cord injury.
Liu H, Li X, Li M, et al. · Bioact Mater 2027
- Genetic engineering of primary human mesenchymal stromal cells using the CRISPR/Cas9 synergistic activation mediator.
Killer MC, Zhang X, Adhikary T, et al. · Genes Dis 2027
- Stromal Cells and Sjögren's Disease.
McCoy SS, Manfrè V · Rheum Dis Clin North Am 2027
- Bone marrow ECM-based vascular niche modeling for the evaluation of HSC/leukemic cell interaction with niche cells.
Huang Y, Peng P, Huang T, et al. · Biomater Adv 2027
- Ultrasound-responsive nanotherapy promotes axonal regeneration after SCI via reactivating CREB/miR-129-5p signaling.
Gu G, Zhu H, Li S, et al. · Bioact Mater 2027
- From pathogenic to reparative: Context-Dependent function of extracellular vesicles in osteoarthritis.
Yang Z, Lin Q, Li H, et al. · Bioact Mater 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.